Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bedaquiline 2-week regimen versus isoniazid 9-month regimen for latent tuberculosis infection
ChiCTR2300073791Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bedaquiline in latent tuberculosis infection (LTBI) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Incidence of tuberculosis. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
bedaquiline
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ChiCTR2300073791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073791.